Merging konjac glucomannan with other copolymeric hydrogels as a cutting-edge liquid raft system for dual delivery of etoricoxib and famotidine

This study aimed to formulate and evaluate a floating raft system for the co-delivery of etoricoxib (ETO) and famotidine (FAM) using a combination of glucomannan with natural/semi-synthetic polysaccharides. Formulation variables affect gelation lag time (GLT), floating lag time (FLT), and release pe...

Full description

Saved in:
Bibliographic Details
Published in:Drug delivery 2023-12, Vol.30 (1), p.2189630
Main Authors: Shoman, Nabil A., Saady, Marwa, Teaima, Mahmoud, Abdelmonem, Rehab, El-Nabarawi, Mohamed A., Elhabal, Sammar Fathy
Format: Article
Language:English
Subjects:
Acids
Analgesics
Arthritis
Bioavailability
Design
Drug delivery systems
Drug Delivery Systems - methods
dual delivery
Etoricoxib
famotidine
Famotidine - pharmacokinetics
glucomannan
Humans
Hydrogels
Lipids
Pediatrics
Pharmaceutical industry
Pharmaceutical sciences
Pharmacy
Polymers
raft forming system
Ulcers
Viscosity
X-ray imaging
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This study aimed to formulate and evaluate a floating raft system for the co-delivery of etoricoxib (ETO) and famotidine (FAM) using a combination of glucomannan with natural/semi-synthetic polysaccharides. Formulation variables affect gelation lag time (GLT), floating lag time (FLT), and release percentage of drugs after 1-8 h, Stability, and viscosity parameters were evaluated. In vivo X-ray studies, followed by the pharmacokinetic study, were performed on human volunteers. Formulations exhibited pseudoplastic behavior for ease of swallowing. The optimum raft system (ORS) comprised 1% Na alginate, 0.1% Low Methoxyl (LM) pectin, 0.8% Konjac glucomannan (KGL), 1% Precirol, and 1% CaCO 3 . ORS exhibited rapid GLT and FLT (around 42 and 8 sec respectively) in 0.1 N HCl as well as controlled release of ETO (15% in 1 h and 82% in 8 h) and FAM (29% in 1 h and 85% in 8 h). Formulation stability with the absence of any drug-excipient interactions was observed. The X-ray imaging showed a promising buoyancy ability for approximately 8 h. Compared with marketed products, ORS showed superior relative bioavailability for both drugs. These findings revealed the successful preparation of a promising raft system with improved dual drug delivery.
ISSN:1071-7544
1521-0464
1521-0464
DOI:10.1080/10717544.2023.2189630